ERIS Lifesciences
ERIS Lifesciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ERIS Lifesciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
ERIS Lifesciences Ltd trades at a P/E of 31.08× and P/B of 4.92×.
Valuation
Profitability
Growth
Financial Health
ERIS Lifesciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for ERIS Lifesciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
ERIS Lifesciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹19,409.86 Cr and reported EPS of ₹45.20.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 |
| Other Income | 26 | 32 | 15 | 9 | 26 | 11 | 24 | 18 | 8 |
| Total Income | 882 | 1,014 | 1,089 | 1,221 | 1,373 | 1,696 | 2,033 | 2,912 | 3,137 |
| Cost of Goods Sold (COGS) | 134 | 154 | 172 | 238 | 259 | 352 | 380 | 714 | 796 |
| Gross Profit | 722 | 828 | 903 | 974 | 1,089 | 1,333 | 1,629 | 2,180 | 2,334 |
| +Operating Expenses | 400 | 484 | 534 | 543 | 604 | 796 | 954 | 1,162 | 1,214 |
| EBITDA | 322 | 345 | 368 | 431 | 485 | 537 | 675 | 1,017 | 1,120 |
| +Non-Operating Expenses | 36 | 59 | 52 | 45 | 69 | 143 | 267 | 547 | 455 |
| Profit Before Tax (PBT) | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 638 |
| +Tax Expense | 17 | 26 | 35 | 39 | 36 | 30 | 34 | 114 | -9 |
| Profit After Tax (PAT) | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 |
| Earnings Per Share (EPS) | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 44.72 |
| Diluted Shares Outstanding (Nos.) | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| +Additional Disclosures | 705 | 850 | 928 | 1,063 | 1,188 | 1,636 | 1,984 | 3,157 | 3,304 |
| Sales Growth % | — | 14.79 | 9.36 | 12.83 | 11.15 | 25.10 | 19.23 | 44.02 | 8.15 |
| YoY Sales Growth % | — | 14.79 | 9.36 | 12.83 | 11.15 | 25.10 | 19.23 | 44.02 | 8.15 |
| Material Cost % | 6 | 6 | 7 | 8 | 9 | 8 | 9 | 10 | 10 |
| Employee Cost % | 18 | 19 | 19 | 19 | 19 | 21 | 20 | 17 | 18 |
| Other Cost % | 28 | 30 | 31 | 26 | 26 | 27 | 27 | 23 | 21 |
| OPM % | 38 | 35 | 34 | 36 | 36 | 32 | 34 | 35 | 36 |
| Tax % | 6 | 8 | 11 | 10 | 8 | 8 | 8 | 23 | -1 |
| Profit Growth % | — | -1.30 | 1.84 | 19.77 | 14.26 | -7.79 | 6.12 | -5.64 | 72.82 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 296 | 309 | 318 | 388 | 420 | 420 | 492 | 702 | 841 |
ERIS Lifesciences segment analysis: revenue and profit mix.
Disclosed business segments at ERIS Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
ERIS Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
ERIS Lifesciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy ERIS Lifesciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
ERIS Lifesciences Ltd's investment case rests on 6 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
ERIS Lifesciences boasts a strong operating profit margin (OPM) of 35.40%, showcasing efficient operations and high profitability. A Return on Equity (ROE) of 12.90% indicates effective capital utilization and superior returns for shareholders.
The company demonstrates impressive quarterly profit growth, achieving a remarkable 41.60% increase. This positive trend, alongside a 7.40% rise in quarterly sales, signifies a healthy expansion trajectory within the pharmaceuticals sector.
Promoter holding remains strong at 54.85% (Sep 2025), indicating management confidence. Additionally, Domestic Institutional Investors (DIIs) have steadily increased their stake to 19.36%, reflecting growing institutional trust.
Operating within the robust Pharmaceuticals and Healthcare sectors, ERIS is well-positioned to capitalize on increasing healthcare expenditure, rising chronic disease prevalence, and growing demand for quality medicines.
The impressive 41.60% quarterly profit growth indicates strong underlying demand and potential for further market share expansion. Strategic product diversification or new market entry could accelerate this growth trajectory.
What can break it.
ERIS's debt-to-equity ratio of 0.87 suggests a relatively high debt level compared to equity. This could heighten financial risk, particularly during economic downturns, potentially limiting financial flexibility and impacting strategic decisions.
The stock's Price-to-Earnings (PE) ratio of 57.40 is high, indicating a potentially overvalued stock relative to its earnings. This valuation makes it vulnerable to corrections if earnings growth doesn't meet investor expectations.
The company's Return on Capital Employed (ROCE) of 12.20% is notably lower than many industry peers, suggesting less efficient capital utilization. This could impact long-term value creation and competitive positioning.
Foreign Institutional Investors (FIIs) have significantly reduced their stake from 15.35% in June 2022 to 7.21% in September 2025. This consistent selling trend could signal waning foreign investor confidence.
The recent stock price volatility, with a 52-week high of ₹1910 and a low of ₹1097, presents a risk for investors seeking stability. This fluctuation underscores market uncertainty and potential for capital loss.
What would change my mind.
Trim if P/E re-rates above 40. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 61.05. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 13%. The operating engine is no longer compounding capital efficiently.
ERIS Lifesciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ERIS Lifesciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
ERIS Lifesciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for ERIS Lifesciences Ltd — derived from the live tape, not yesterday's close.
ERIS Lifesciences Ltd last traded at ₹1,404.6 with an intraday range of ₹1,365.3–₹1,411.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1404.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1514.43 | +109.83 | +7.82% |
| R3 | 1468.33 | +63.73 | +4.54% |
| R2 | 1439.87 | +35.27 | +2.51% |
| R1 | 1422.23 | +17.63 | +1.26% |
| PIVOT | 1393.77 | -10.83 | -0.77% |
| CURRENT | 1404.60 | — | — |
| S1 | 1283.93 | -120.67 | -8.59% |
| S2 | 1330.03 | -74.57 | -5.31% |
| S3 | 1347.67 | -56.93 | -4.05% |
| S4 | 1376.13 | -28.47 | -2.03% |
ERIS is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1369.7 ~ 1388
Trading Above opening range, showing Bullishness
ERIS Lifesciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ERIS Lifesciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ERIS Lifesciences Ltd stood at 53.4% of traded volume, against a 20-day average of 46.5%.
ERIS Lifesciences announcements: results, concalls, ratings, M&A.
Filings ERIS Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ERIS Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 145 documents below.
Action(s) taken or orders passed
Eris Lifesciences Limited has informed the Exchange about Action(s) taken or orders passed
Disclosure under SEBI Takeover Regulations
Eris Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Analysts/Institutional Investor Meet/Con. Call Updates
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Investor Presentation
Eris Lifesciences Limited has informed the Exchange about Investor Presentation
Record Date
Eris Lifesciences Limited has informed the Exchange that Record date for the purpose of Dividend is 29-May-2026.
Investor decks & rating reports.
ERIS Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ERIS Lifesciences has declared, sequenced by announce and record date.
ERIS Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ERIS Lifesciences Ltd: business, sector, key facts.
What ERIS Lifesciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ERIS Lifesciences Ltd operates in the Healthcare, listed as NSE: ERIS, BSE: 540596.
Eris Lifesciences Limited is a pharmaceutical company headquartered in Ahmedabad, India, that focuses on providing domestically branded formulations for chronic and sub-chronic therapeutic treatments within the Indian market. Their business model centers on developing and marketing a wide range of branded medications across several key therapeutic areas.
The company's product portfolio covers a diverse spectrum of medical needs. This includes treatments for anti-diabetes, cardiovascular diseases, dermatological conditions, neurological disorders, gynecological issues, nephrological problems, and oncology. Additionally, they offer products focused on central nervous system health, women's health, and nutritional supplements like vitamins and minerals.
Beyond just medication, Eris Lifesciences also provides various patient care services to enhance healthcare access and management. These services include ambulatory blood pressure and electrocardiogram monitoring, continuous glucose monitoring, sleep studies, and antenatal care solutions. This integrated approach differentiates them in the market by offering a more holistic patient experience.
Eris Lifesciences distributes its products through a well-established network encompassing wholesale drug distributors, stockists, and retail pharmacies, ensuring wide accessibility across India. This robust distribution network is a key component of their strategy for reaching a broad patient base and maintaining market presence.
Founded in 2007, Eris Lifesciences has built a significant presence in the Indian pharmaceutical market through its commitment to providing affordable and effective medications combined with supportive patient care services. Their focus on chronic and sub-chronic therapies signifies a dedication to addressing the long-term health needs of a considerable segment of the population.
Questions investors ask about ERIS Lifesciences Ltd (ERIS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ERIS Lifesciences Ltd (ERIS)?
The current share price of ERIS Lifesciences Ltd (ERIS) is ₹1,404.6. Today, the stock has gained by ₹39.00 (2.86%), trading in a range of ₹1,365.3 to ₹1,411.4. The stock opened at ₹1,388 with a trading volume of 63,719 shares.
02Is ERIS Lifesciences Ltd stock a good investment for long-term?
ERIS Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹19,409.86 crores, P/E ratio of 31.08, ROE of 18.07%, and ROCE of 12.20%. The dividend yield stands at 1.06%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ERIS Lifesciences Ltd stock?
The 52-week high price of ERIS Lifesciences Ltd (ERIS) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,404.6, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ERIS Lifesciences Ltd stock at the current price?
Whether to buy ERIS Lifesciences Ltd stock at ₹1,404.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 31.08 and P/B ratio of 4.92. Today's performance shows a gain of 2.86%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ERIS Lifesciences Ltd and when is the next dividend?
ERIS Lifesciences Ltd offers a dividend yield of 1.06%, which means for every ₹100 invested at the current price of ₹1,404.6, you can expect to receive approximately ₹1.06 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd's key financial metrics include: P/E Ratio: 31.08, P/B Ratio: 4.92, ROE: 18.07%, ROCE: 12.20%, Dividend Yield: 1.06%, EPS: ₹45.20, Book Value: ₹285.48, and Debt-to-Equity: 60.55. The company's market cap stands at ₹19,409.86 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ERIS Lifesciences Ltd stock performing today in the market?
ERIS Lifesciences Ltd stock opened at ₹1,388 and is currently trading at ₹1,404.6, showing a gain of ₹39.00 (2.86%). The intraday high is ₹1,411.4 and low is ₹1,365.3. The trading volume stands at 63,719 shares, indicating moderate market participation today.
08What is the P/E ratio of ERIS Lifesciences Ltd and what does it indicate?
ERIS Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 31.08, which means investors are willing to pay ₹31.08 for every ₹1 of earnings. With an EPS of ₹45.20, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ERIS Lifesciences Ltd (ERIS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy